An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients.
An improved HPLC fluorimetric method for the quantification of enfuvirtide in plasma of HIV-infected subjects was described and validated. The use of an internal standard improved the reproducibility and precision of the analysis. Our method showed lower limits of detection and quantification (LOD = 32 ng/mL, LOQ = 78 ng/mL), lower intraday (RSD% 1.25-2.95) and interday (RSD% 1.75-4.69) coefficients of variation, greater recovery (>100%), lower duration (16 minutes) and lower cost than previously described fluorimetric methods. Therefore, this method can be used as a reliable tool for pharmacokinetic studies of enfuvirtide.
D'Avolio
Antonio
A
Department of Infectious Diseases, University of Torino, Amedeo di Savoia Hospital, Turin, Italy. antodav@inwind.it
Sciandra
Mauro
M
de Requena
Daniel Gonzalez
DG
Ibañez
Allende
A
Bonora
Stefano
S
Di Perri
Giovanni
G
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004347:Drug Interactions; D000077560:Enfuvirtide; D005470:Fluorometry / Q000379:methods; D015700:HIV Envelope Protein gp41 / Q000097:blood*; D023581:HIV Fusion Inhibitors / Q000097:blood*; D015658:HIV Infections / Q000097:blood*; D006801:Humans; D010446:Peptide Fragments / Q000097:blood*; D015203:Reproducibility of Results
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide